Ashish Kamat, MD
Urology · Houston, TXNPI 1114012895
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $421,770 of the $481,452 with a category attached, or 87.6%. 27 manufacturers reported payments, led by Merck at 29.4% of the total. 2025 is the largest year on record at $122,152, 2.3 times the $53,477 reported in 2019. Among urology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 254 payments — averaging $1895.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$142K
- Janssen Research & Development, LLC$108K
- Ferring Pharmaceuticals Inc.$52K
- AstraZeneca$34K
- Pfizer$20K
- Urogen Pharma, Inc.$19K
- plus $107K from 21 others
Across 47 payments — averaging $10,120 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$339K
- Pfizer$99K
- KARL Storz Endoscopy-america$27K
- E.r. Squibb & Sons, L.L.C.$7K
- Incyte Corporation$3K
What the payments were for
- Consulting fees$421,77088%
- Speaking & faculty fees$26,3295%
- Travel & lodging$30,0126%
- Food & beverage$3,3411%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 74 | $141,673 |
| Janssen Research & Development, LLC | 30 | $108,281 |
| Ferring Pharmaceuticals Inc. | 32 | $51,720 |
| AstraZeneca | 13 | $33,749 |
| Pfizer | 13 | $20,006 |
| Urogen Pharma, Inc. | 7 | $19,387 |
| Janssen Global Services, LLC | 21 | $17,560 |
| Seagen Inc. | 8 | $16,871 |
| Janssen Scientific Affairs, LLC | 4 | $10,715 |
| Astellas Pharma US Inc | 4 | $9,851 |
| Photocure Inc | 8 | $8,819 |
| Abbott | 6 | $7,094 |
| E.r. Squibb & Sons, L.L.C. | 8 | $6,818 |
| Eisai Inc. | 6 | $6,580 |
| Astellas Pharma Global Development | 4 | $6,295 |
| Ferring Pharmaceuticals AS | 1 | $6,293 |
| Nonagen Bioscience Corp | 2 | $2,625 |
| F. Hoffmann-la Roche AG | 1 | $1,950 |
| Astrazeneca UK Limited | 1 | $1,663 |
| Verity Pharmaceuticals Inc. | 1 | $1,600 |
| Genentech, Inc. | 2 | $1,094 |
| Johnson & Johnson(2 entities) | 2 | $561 |
| Boston Scientific | 1 | $120 |
| Convatec Inc. | 1 | $44 |
| Exelixis Inc. | 2 | $40 |
| 180 Medical, Inc. | 1 | $29 |
| Astellas Pharma Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$481,452 in reported general payments places this provider in the 95th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levofloxacin | 24 | $28 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $13 |
Paid to pharmacies, not to this prescriber.
Other urology in Houston
- Arun RaiHouston$920K
- Donald GriffithHouston$732K
- Jonathan Clavell HernandezHouston$500K
- Mohit KheraHouston$428K
- Ricardo GonzalezHouston$314K
- Richard LinkHouston$261K
- Steven CanfieldHouston$256K
- Run WangHouston$195K
- Kathleen KobashiHouston$159K
- Steven MaislosHouston$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.